Current Issue January 2012, Vol. 102, No. 1

Issue Highlights

Original articles

Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial
January 2012(Vol. 102 | No. 1 | Pages 4-9)
Jin-luan Li, Jia-fu Ji, Yong Cai, Xiao-fan Li, Yong-heng Li, Hao Wu, Bo Xu, Fang-yuan Dou, Zi-yu Li, Zhao-de Bu, Ai-wen Wu, Ivan W.K. Tham

Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial
January 2012(Vol. 102 | No. 1 | Pages 10-13)
Gudrun Resch, Alexander De Vries, Dietmar Öfner, Wolfgang Eisterer, Hans Rabl, Michael Jagoditsch, Michael Gnant, Josef Thaler, on behalf of the Austrian Breast and Colorectal Cancer Study Group

Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands
January 2012(Vol. 102 | No. 1 | Pages 14-21)
Jasper Nijkamp, Danielle F.M. de Haas-Kock, Jannet C. Beukema, Karen J. Neelis, Dankert Woutersen, Heleen Ceha, Tom Rozema, Annerie Slot, Hanneke Vos-Westerman, Martijn Intven, Patty H. Spruit, Yvette van der Linden, Debby Geijsen, Karijn Verschueren, Marcel B. van Herk, Corrie A.M. Marijnen

Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: Outcomes of 55Gy in 16 fractions at 3.4Gy per fraction
27 January 2012
Jackson S.Y. Wu, Penelope M.A. Brasher, Ali El-Gayed, Nadeem Pervez, Patricia T. Tai, John Robinson, David Skarsgard, Kurian Joseph, Michael A. Sia, Robert G. Pearcey
Abstract: Purpose: To estimate the late morbidity of a novel, hypofractionated external beam radiotherapy schedule of 55Gy in 16 fractions (4 fractions/week, 3.4Gy per fraction) for localized prostate...
Dose–response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer
27 January 2012
Shreerang A. Bhide, Sarah Gulliford, Ulrike Schick, Aisha Miah, Shane Zaidi, Katie Newbold, Christopher M. Nutting, Kevin J. Harrington
Abstract: Dose–response curves (DRCs) and the quantitative parameters describing these curves were generated for grade 3 oral mucositis and dysphagia in 144 patients using individual patient DVHs. Cur...
Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma
27 January 2012
Jeffrey Kit Loong Tuan, Tam Cam Ha, Whee Sze Ong, Tian Rui Siow, Ivan Weng Keong Tham, Swee Peng Yap, Terence Wee Kiat Tan, Eu Tiong Chua, Kam Weng Fong, Joseph Tien Seng Wee
Abstract: Background and purpose: We sought to evaluate the nature and frequency of late toxicities in a cohort of nasopharyngeal cancer (NPC) patients treated with conventional radiotherapy alone. Me...
FDG–PET–CT reduces the interobserver variability in rectal tumor delineation
27 January 2012
Jeroen Buijsen, Jørgen van den Bogaard, Hiska van der Weide, Stephanie Engelsman, Ruud van Stiphout, Marco Janssen, Geerard Beets, Regina Beets-Tan, Philippe Lambin, Guido Lammering
Abstract: Background and purpose: Previously, we showed a good correlation between pathology and an automatically generated PET-contour in rectal cancer. This study analyzed the effect of the use of P...
Fat necrosis in women with early-stage breast cancer treated with accelerated partial breast irradiation (APBI) using interstitial brachytherapy
27 January 2012
Ashwini Budrukkar, Vikas Jagtap, Seema Kembhavi, Anusheel Munshi, Rakesh Jalali, Tanuja Seth, Vani Parmar, Ritu Raj Upreti, Rajendra Badwe, Rajiv Sarin
Abstract: Purpose: To report the incidence of clinical, pathological and radiological fat necrosis (FN) in women treated with accelerated partial breast irradiation (APBI) using interstitial brachythe...

View More Articles in Press...

1

Article Title	Author(s)	Type	Pages
Radiation-induced heart morbidity after adjuvant radiotherapy of early breast cancer – Is it still an issue? August 2011 (Vol. 100 \| No. 2 \| Pages 157-159) Full Text PDF (144 KB)	Birgitte Offersen, Inger Højris, Marie Overgaard	Editorial	157-159
Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention August 2011 (Vol. 100 \| No. 2 \| Pages 160-166) Abstract Full Text PDF (186 KB)	Nicolaus Andratschke, Jean Maurer, Michael Molls, Klaus-Rüdiger Trott	Review article	160-166
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden August 2011 (Vol. 100 \| No. 2 \| Pages 167-175) Abstract Full Text PDF (854 KB) Supplemental Materials	Paul McGale, Sarah C. Darby, Per Hall, Jan Adolfsson, Nils-Olof Bengtsson, Anna M. Bennet, Tommy Fornander, Bruna Gigante, Maj-Britt Jensen, Richard Peto, Kazem Rahimi, Carolyn W. Taylor, Marianne Ewertz et al.	Full-length article	167-175
The future development of radiation oncology in Europe: A personal view July 2011 (Vol. 100 \| No. 1 \| Pages 7-9) Full Text PDF (128 KB)	Jan Willem H. Leer	Editorial	7-9
Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) July 2011 (Vol. 100 \| No. 1 \| Pages 76-85) Abstract Full Text PDF (465 KB)	M. Baumann, T. Herrmann, R. Koch, W. Matthiessen, S. Appold, B. Wahlers, L. Kepka, G. Marschke, D. Feltl, R. Fietkau, V. Budach, J. Dunst, R. Dziadziuszko, M. Krause, D. Zips, on behalf of the CHARTWEL-Bronchus studygroup et al.	Full-length article	76-85

1

Most Read lists are compiled every quarter.

Publishing Information

Radiotherapy & Oncology is published by Elsevier.

Click here to read a selection of papers from the launch of Radiotherapy in 1983 to 2011

About Radiotherapy & Oncology

Radiotherapy & Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as physical aspects relevant to oncology, particularly in the field of imaging, dosimetry and radiation therapy planning.

More